Isomorphic Labs secures five billion dollars and enters oncology partnership
Alphabet spin-off Isomorphic Labs has secured 5 billion dollars in Series C funding while launching an artificial intelligence oncology collaboration with MSD.
FTMQ Startups, written by our newsroom0 views

Isomorphic Labs has raised 5 billion dollars in Series C funding, according to Brief IA and Tech.eu. The London-based artificial intelligence company has also formed a partnership with MSD to discover small-molecule oncology therapies, Silicon Republic reported. [1][2][3][5]
The research collaboration combines the AI technology of Isomorphic Labs with the data resources and domain experience of MSD, Silicon Republic reported. The joint project aims to discover therapeutic candidates against a strategic oncology target by predicting and designing small molecules. [2]
Isomorphic Labs was founded in February 2021 as a spin-off from DeepMind under Alphabet Inc. Demis Hassabis serves as the chief executive officer. The company relies on advanced artificial intelligence models, including the AlphaFold system, to model biological processes and design novel therapeutics. [5][8]
In February 2026, Isomorphic Labs released IsoDDE, an AI computational tool designed to improve protein-ligand structure predictions and binding affinity estimation beyond AlphaFold 3 capabilities. The new Series C investment comes alongside wider capital deployment across European technology startups, as reported by Analytics Insight and Tech.eu. [1][4][8]
In short
- Isomorphic Labs raised 5 billion dollars in Series C funding.
- The company partnered with MSD to work on AI-led oncology drug discovery.
- Demis Hassabis founded Isomorphic Labs in 2021 as an Alphabet spin-off from DeepMind.
- Isomorphic Labs released its IsoDDE drug design engine in February 2026.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Startup ecosystem calls to withdraw and re-table EU Inc proposal, Isomorphic Labs bags $5B, and inside Plural's €1B fundTech.eu, 1d ago (the report this story comes from)
- [2]Isomorphic Labs and MSD team up on AI-led cancer drug discoverySilicon Republic, 2d ago
- [3]Isomorphic Labs Raises $5 Billion in Series C FundingBrief IA, 1d ago
- [4]Weekly Startups Roundup: Isomorphic Labs, Payhawk, Model ML Raise Fresh FundsAnalytics Insight, 2d ago
Background
- [5]Isomorphic Labs on Wikipedia
- [6]Israel on Wikipedia
- [7]History of banking on Wikipedia
- [8]Isomorphic Labs on Grokipedia
Our newsroom writes these reports with the help of software, from the 8 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Startups
Earlier reports of ours on the same people and subjects.
- Irish AI project Oghma secures 500,000 euro investment prize in BerlinFunding Rounds, 17d ago
- Salience Labs secures 125 million dollars in Series B fundingExits and Failures, 38d ago
- Modal raises 750 million dollars in Series D funding roundFunding Rounds, 38d ago
- Realty Income secures funding and completes European venture with KKRVenture Capital, 48d ago
- Dream Labs raises 90 million dollars in seed funding for robotics AIFunding Rounds, 33d ago
More in Exits and Failures
- Stripe founders back artificial intelligence startup Hoplite14h ago
- European Commission unveils five measures to support business angel investment7d ago
- Michigan regulator approves Soaring Eagle platform switch to White Hat Gaming7d ago
- Second Circuit denies Kalshi and Coinbase interim relief in state cases12d ago
- Perlego expands digital library as total funding surpasses 70 million euros12d ago
- Crowd Threat raises 1 million pounds in seed funding12d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.